Home » Expert Content » Drug Substance ManufacturingPage 2

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

EXPERT CONTENT

Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.

VISIT OUR YOUTUBE CHANNEL

BROWSE BY

TOPIC:






TYPE:





Biosimilars: Getting Cheaper Biologics To The Market

Summary: The opportunity for new antibody biosmilar products is clear. By the end of this decade key patents currently protecting five monoclonal antibodies, each with sales in the neighborhood of a billion dollars a year will have expired, and companies are queuing up for a piece of the market…

read more

Biopharmaceuticals/ Biosimilars Roundtable, APR 2017

Summary: The biopharmaceutical market has seen incredible growth. American Pharmaceutical Review conducted industry round table with experts to share their opinion on the market drivers for growth, limiting factors and critical issues. Read the article to get insights on developing and marketing biopharmaceutical…

read more

Developing Site-Specifically Modified ADCs Using A Chemoenzymatic Approach

Summary: Antibody-drug conjugates (ADCs) have become de rigueur for pharmaceutical oncology drug development pipelines. There are more than 40 ADCs undergoing clinical trials and many more in preclinical development. This webinar hosted by Elsevier’s Drug Discovery Today presented novel protein modification platform and its application…

read more

Evolution Of Biomanufacturing Facilities

Summary: Advances in single-use bioreactor technologies offer rapid development pathways when combined with creative upstream process development strategies. When aggressive program timelines are required, the application of multiplexed conditions coupled with smart CMC decisions that maximize yields…

read more

Optimized Antibody Drug Conjugate Development

Summary: One of the current challenges with existing ADCs is the difficulty in creating conjugates with a uniform drug to antibody ratio and consistent payload placement on the antibody, both aspects which are paramount in creating consistent and predictable therapies…

read more